Squarepoint
HAE icon

Squarepoint’s Haemonetics HAE Stock Holding History

Squarepoint’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,300
Closed -$892K – 4508
2025
Q3 		$892K Buy
+18,300
New +$1.13M ﹤0.01% 2783
2025
Q1 		– Sell
-12,200
Closed -$953K – 4922
2024
Q4 		$953K Buy
+12,200
New +$980K ﹤0.01% 3111

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's HAE Position: Q2 2026 in Review

Squarepoint increased its Haemonetics (HAE) stake by 194% in Q2 2026, buying an estimated $3.65M and bringing the position to 86,124 shares worth $6.46M. The position accounts for 0.01% of the portfolio, ranked #1385.

Squarepoint first reported a position in HAE in Q3 2017 and has held it in 22 quarters since. The position peaked at $14.7M in Q1 2025. 330 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Squarepoint held 86,124 shares of Haemonetics worth $6.46M as of Q2 2026.
  • Squarepoint bought 56,843 Haemonetics shares in Q2 2026, an estimated $3.65M.
  • Haemonetics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1385 holding.
  • Squarepoint first reported a position in Haemonetics in Q3 2017 and has held it in 22 quarters since.
  • Squarepoint's Haemonetics position peaked at $14.7M in Q1 2025.
  • 330 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.